FDC Ltd Valuation Shifts to Fair Amidst Sector Volatility

Valuation Metrics Reflecting a More Balanced Outlook

As of 19 Mar 2026, FDC Ltd’s price-to-earnings (P/E) ratio stands at 23.57, a figure that positions the stock within a fair valuation range compared to its pharmaceutical peers. This is a significant moderation from previous levels that had placed it in the expensive category. The price-to-book value (P/BV) ratio is currently 2.26, indicating a reasonable premium over book value, consistent with industry norms for companies with stable earnings and growth prospects.

Other enterprise value (EV) multiples further support this balanced valuation stance. The EV to EBIT ratio is 23.11, while EV to EBITDA is 18.13, both suggesting that the market is pricing FDC Ltd with moderate expectations for operational profitability. The EV to capital employed and EV to sales ratios, at 2.51 and 2.45 respectively, reinforce the notion that the stock is fairly valued relative to its asset base and revenue generation.

Notably, the PEG ratio is reported as zero, which may reflect either a lack of meaningful earnings growth projections or data limitations. Dividend yield remains modest at 1.48%, aligning with the company’s reinvestment strategy and sector norms.

Comparative Peer Analysis Highlights Relative Attractiveness

When benchmarked against key industry players, FDC Ltd’s valuation appears more attractive. For instance, Ajanta Pharma trades at a P/E of 37.5 and EV to EBITDA of 27.49, categorised as expensive. J B Chemicals & Pharmaceuticals is even pricier, with a P/E of 45.23 and EV to EBITDA of 29.59, labelled very expensive. Similarly, Emcure Pharma and Gland Pharma maintain elevated valuations with P/E ratios above 30 and EV to EBITDA multiples near or above 17.

Global pharmaceutical giants such as Pfizer and AstraZeneca Pharma exhibit very expensive valuations, with Pfizer’s P/E at 28.74 and AstraZeneca’s soaring to 101.98, reflecting their dominant market positions and growth expectations. In contrast, FDC Ltd’s fair valuation grade signals a more cautious market view, potentially offering value for investors seeking exposure to the sector without the premium pricing of larger peers.

Interestingly, Piramal Pharma is noted as attractive but is currently loss-making, which complicates direct valuation comparisons. ERIS Lifescience, another peer, holds a fair valuation with a P/E of 40.7 and EV to EBITDA of 18.58, somewhat higher than FDC Ltd but still within a reasonable range.

Financial Performance and Returns Contextualise Valuation

FDC Ltd’s return metrics over various periods reveal a mixed performance relative to the broader market. Year-to-date (YTD), the stock has declined by 20.35%, significantly underperforming the Sensex’s 9.99% fall. Over the past year, the stock is down 18.47%, while the Sensex has gained 1.86%, highlighting sector-specific or company-specific headwinds.

Longer-term returns paint a more positive picture, with a three-year return of 34.59% slightly outperforming the Sensex’s 32.27%. However, over five and ten years, FDC Ltd’s returns of 21.63% and 85.20% lag behind the Sensex’s 55.85% and 207.40% respectively, indicating challenges in sustaining growth momentum over extended periods.

Operationally, the company’s return on capital employed (ROCE) stands at 10.64%, and return on equity (ROE) at 9.27%, both modest figures that suggest moderate efficiency in generating profits from capital and shareholder equity. These metrics align with the fair valuation grade, reflecting tempered expectations for profitability improvement.

Market Capitalisation and Recent Price Movements

FDC Ltd is classified as a small-cap stock, with a current price of ₹337.15, down 0.95% on the day from the previous close of ₹340.40. The stock has traded within a 52-week range of ₹330.05 to ₹528.30, indicating significant volatility and a recent downtrend from its highs. Today’s intraday range was ₹335.15 to ₹347.80, showing some buying interest near the lower end but limited upside momentum.

This price behaviour, combined with the valuation shift, suggests that investors are recalibrating their expectations, possibly factoring in sector headwinds, competitive pressures, and company-specific challenges.

Mojo Score and Rating Update Reflect Market Sentiment

MarketsMOJO’s proprietary scoring system currently assigns FDC Ltd a Mojo Score of 26.0, categorising it with a Strong Sell grade. This represents a downgrade from the previous Hold rating as of 03 Nov 2025, signalling a deteriorating outlook based on fundamental and technical factors.

The downgrade is consistent with the company’s valuation adjustment and recent price underperformance. The Strong Sell rating suggests that investors should exercise caution and consider the risks associated with holding or initiating positions in FDC Ltd at current levels.

Given the small-cap status and sector volatility, the stock’s risk-reward profile appears unfavourable relative to more attractively valued or fundamentally stronger peers.

Conclusion: Valuation Shift Offers a Nuanced Investment Case

FDC Ltd’s transition from an expensive to a fair valuation grade marks a significant development in its market perception. While the stock’s P/E and P/BV ratios now align more closely with sector averages, the broader context of subdued returns, modest profitability metrics, and a Strong Sell rating tempers enthusiasm.

Investors should weigh the company’s fair valuation against its operational challenges and competitive landscape. The pharmaceutical sector remains dynamic, with high-growth peers commanding premium valuations, while companies like FDC Ltd face pressure to improve earnings and capital efficiency.

For those seeking exposure to the Pharmaceuticals & Biotechnology sector, a thorough comparative analysis is essential to identify stocks with superior growth prospects and valuation support.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →